With Alzheimer's disease cases in the U.S. projected to more than double to 14 million by 2060, the search for modifiable protective factors has never been more urgent. Understanding how exercise biologically defends the brain — beyond general cardiovascular benefits — could reshape preventive strategies for millions of aging adults who cannot sustain vigorous physical activity.
This review in Biomolecules synthesizes current evidence on irisin, a myokine cleaved from the membrane protein FNDC5 during muscle contraction and released into systemic circulation as an exerkine. Irisin crosses the blood-brain barrier and appears to counter several hallmark AD pathologies simultaneously: it suppresses amyloid-beta aggregation, reduces tau hyperphosphorylation, supports hippocampal neurogenesis, improves mitochondrial function in neurons, and promotes cerebral blood flow. Preclinical studies in transgenic AD mouse models using direct irisin administration — bypassing exercise itself — have replicated multiple neuroprotective outcomes, suggesting the molecule functions as an autonomous signaling agent rather than merely a biomarker of physical exertion.
The broader significance here is mechanistic: irisin may represent one of the primary molecular bridges between skeletal muscle activity and brain resilience, a concept gaining traction in the muscle-brain axis literature. This is potentially important for populations where exercise capacity is limited — frail elderly adults, those with mobility impairments, or individuals already in early cognitive decline. However, the translational gap remains substantial. Nearly all intervention data derive from mouse models, and human studies measuring circulating irisin face serious methodological challenges, including inconsistent antibody specificity in ELISA assays. Causal directionality in humans is unestablished, and optimal delivery mechanisms for any future irisin-based therapy are unresolved. This review is confirmatory and synthesizing rather than paradigm-shifting, but it usefully consolidates a fragmented literature and frames irisin as a tractable pharmacological target worth rigorous clinical investigation.
